Recursion is a clinical-stage biotechnology company that develops novel medicines using an integrated AI-native platform spanning biological discovery through clinical development. The Recursion Operating System combines large-scale cellular and genomic data analysis, generative AI-driven molecular design (Centaur Chemist), and AI-enabled clinical trial optimization (ClinTech) to identify drug targets, design small molecules, and optimize patient selection more rapidly and cost-effectively than traditional approaches. The company generates revenue through partnerships with major pharmaceutical companies including Roche, Sanofi, Bayer, and Merck KGaA, receiving upfront payments, milestone-based fees tied to clinical and commercial success, and royalties on approved drugs, while advancing its own pipeline of oncology and rare disease programs alongside partnered discovery efforts.